Source: Reuters (via feed)
Indian drugmakers Zydus Lifesciences and Lupin signed a licensing and supply deal on Tuesday. The agreement covers co-marketing of semaglutide injections in India. This arrangement precedes the expiry of semaglutide’s patent.
BizTrendWire Insight:
The licensing and supply deal involves two Indian drugmakers cooperating on semaglutide injections. It relates to market activities ahead of patent expiration.
The licensing and supply deal involves two Indian drugmakers cooperating on semaglutide injections. It relates to market activities ahead of patent expiration.
